MedPath

Idiopathic Pulmonary Fibrosis Job Exposures Study

Completed
Conditions
Idiopathic Pulmonary Fibrosis
IPF
Interventions
Other: Computer-assisted telephone interview
Genetic: Genetic analysis
Registration Number
NCT03211507
Lead Sponsor
Imperial College London
Brief Summary

A case-control study to investigate whether job exposures are an under-recognized cause of idiopathic pulmonary fibrosis (IPF) using an interview to collect information about previous jobs and a blood test to investigate genetic susceptibility.

Detailed Description

Idiopathic pulmonary fibrosis (IPF) is a scarring lung disease. It damages the air sacs that allow oxygen to be transferred into the blood and transported to vital organs. These changes make people with IPF cough and feel short of breath. It not known what causes the damage. People who get IPF are usually older than 40; it's a very serious illness that cannot be cured and gets worse over time. Statistics show that IPF is becoming more common in the UK but it's not known why. It can be difficult for doctors to tell if someone has IPF or another disease called asbestosis.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
960
Inclusion Criteria
  • New diagnosis of IPF between February 2017 and October 2019
Read More
Exclusion Criteria
  • Unable to give informed consent
  • Ever worked outside of the UK

For controls

Inclusion Criteria:

  • New outpatient department attendee between February 2017 and October 2019

Exclusion Criteria:

  • Unable to give informed consent
  • Ever worked outside of the UK (does not include work outside the UK by members of the armed forces or merchant navy)
  • Diagnosis of IPF
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
CaseComputer-assisted telephone interviewMales with an incident diagnosis of IPF made between the 1st of February 2017 and the 5th of October 2019.
ControlsComputer-assisted telephone interviewMales with an incident hospital outpatient attendance between the 1st of February 2017 and the 5th of October 2019 who do not have a diagnosis of IPF. At each participating centre a control clinic is randomly selected from all control clinics that the research team is able to recruit from; this clinic is the source clinic for controls for the duration of the study.
ControlsGenetic analysisMales with an incident hospital outpatient attendance between the 1st of February 2017 and the 5th of October 2019 who do not have a diagnosis of IPF. At each participating centre a control clinic is randomly selected from all control clinics that the research team is able to recruit from; this clinic is the source clinic for controls for the duration of the study.
CaseGenetic analysisMales with an incident diagnosis of IPF made between the 1st of February 2017 and the 5th of October 2019.
Primary Outcome Measures
NameTimeMethod
Association between asbestos exposure and IPF2 years

estimated using logistic regression for any vs no asbestos exposure and adjusting for age and smoking status

Secondary Outcome Measures
NameTimeMethod
Dose-response relationship between asbestos exposure and IPF2 years

estimated using logistic regression for categories of cumulative exposure and adjusting for age and smoking status

Gene-environment interaction (for MUC5B rs35705950 and asbestos exposure) odds ratio.2 years

MUC5B rs35705950 and asbestos exposure odds ratio.

Trial Locations

Locations (1)

Imperial Healthcare NHS Trust

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath